Denali Therapeutics (NASDAQ:DNLI) Shares Gap Up Following Better-Than-Expected Earnings

Key Points

• Denali shares jumped after its quarterly results beat estimates: EPS was reported at $0.37 versus consensus for a $0.27 loss, while revenue reached $17.78 million compared with forecasts of $12.67 million. The reported profit included a large one-time gain from selling a Priority Review Voucher, so it may not reflect recurring earnings.
• AVLAYAH sales and guidance point to expected growth: The product generated $17.8 million in its second full commercial quarter, and Denali forecast fourth-quarter revenue of $30 million to $32 million.
• Analyst sentiment is broadly positive: Denali has a “Moderate Buy” consensus rating and an average price target of $35.69, though the article also notes a recent insider sale and a sell rating from Weiss Ratings.

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) shares gapped up prior to trading on Wednesday following a stronger than expected earnings report. The stock had previously closed at $19.45, but opened at $21.23. Denali Therapeutics shares last traded at $20.2310, with a volume of 975,686 shares trading hands.

The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.64. The company had revenue of $17.78 million during the quarter, compared to analyst estimates of $12.67 million. During the same period in the prior year, the business posted ($0.74) earnings per share.

More Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: AVLAYAH generated $17.8 million in net product revenue in its second full commercial quarter. Denali forecast fourth-quarter revenue of $30 million to $32 million, signaling expected acceleration in sales. Denali Q3 2026 results
• Positive Sentiment: BTIG Research reaffirmed its Buy rating and set a $39 price target, substantially above the cited current price of $19.45. BTIG Research ratings
• Positive Sentiment: Denali said its zafinofusp BLA submission remains on track for 2027, and expects data in 2027 from five TransportVehicle programs. These milestones offer potential future catalysts, though they remain subject to development and regulatory risk. Denali Q3 2026 results
• Negative Sentiment: Quarterly net income of $70.1 million included a one-time $194 million gain from selling a Priority Review Voucher, so it may overstate recurring earnings strength. Zacks separately reported a $0.64 per-share loss, narrower than expected and improved from a year earlier. Zacks Q3 earnings report

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on DNLI shares. B. Riley Financial boosted their target price on Denali Therapeutics from $30.00 to $35.00 and gave the stock a "buy" rating in a report on Tuesday, August 25th. JPMorgan Chase & Co. began coverage on shares of Denali Therapeutics in a research report on Monday, July 13th. They set an "overweight" rating and a $29.00 price target on the stock. UBS Group boosted their price objective on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Denali Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, July 16th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Denali Therapeutics in a research note on Thursday, October 15th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Denali Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $35.69.

Insiders Place Their Bets

In other news, insider Alexander O. Schuth sold 2,857 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total transaction of $71,624.99. Following the sale, the insider owned 281,763 shares in the company, valued at $7,063,798.41. This trade represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 9.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Denali Therapeutics

A number of large investors have recently added to or reduced their stakes in DNLI. GAMMA Investing LLC lifted its position in Denali Therapeutics by 44.4% in the 3rd quarter. GAMMA Investing LLC now owns 2,236 shares of the company's stock valued at $46,000 after purchasing an additional 687 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Denali Therapeutics by 8.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,220 shares of the company's stock worth $177,000 after purchasing an additional 739 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Denali Therapeutics in the 2nd quarter worth about $26,000. Global Retirement Partners LLC acquired a new stake in shares of Denali Therapeutics in the second quarter valued at approximately $28,000. Finally, Nykredit A S acquired a new stake in shares of Denali Therapeutics in the second quarter valued at approximately $38,000. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Stock Performance

The stock has a fifty day moving average price of $20.42 and a two-hundred day moving average price of $21.24. The company has a market cap of $3.24 billion, a P/E ratio of -7.13 and a beta of 1.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32.

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company's research programs target conditions including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.